The major outer-membrane protein (MOMP) of Chlamydia trachomatis is the focus of attention for chlamydial vaccine design, particularly those serovar-and subspecies-specific epitopes which provoke neutralizing immune responses. Selected surface-exposed B-cell epitopes of MOMP, incorporating B-subspecies specificities, were expressed as fusions with LamB, an inducible outer-membrane transport protein of Escherichia culi. These recombinant chlamydial-LamB proteins were correctly transported to the outer membrane of both E. culi and an aruA mutant of Salmonella typhimurium. The immunogenicity of the constructs was investigated in a mouse model of chlamydial salpingitis. After oral immunization, recombinant S. typhimurium were recovered from the livers of mice for up to two weeks, and a serum IgG response was induced both to the Salmunella and to the inserted chlamydial epitopes. By contrast, intravenous inoculation was ineffective. Although these LamB fusions proved only weakly immunogenic, this approach should be useful for investigating the ability of attenuated S. typhimurium vaccines incorporating chlamydial epitopes to stimulate protective mucosal immunity in the mouse model of chlamydial salpingitis.
Introduction
Chlamydia trachomatis serovars A, B and C are the infectious agents of trachoma, a major cause of preventable blindness world-wide. These three serovars belong either to the B complex (serovar B), or to the C complex (serovars A and C), according to which subspecies epitopes they express. Trachoma vaccines which use killed whole chlamydiae afford only short term, serovarspecific immunity associated with local tear antibody, and in some cases, when subjects subsequently become infected with heterologous serovars, increase disease severity (reviewed by Schachter & Dawson, 1978) . A subunit vaccine which incorporated protective epitopes towards all three trachoma serovars but excluded antigens which induce damaging hypersensitivity responses (Morrison et al., 1989) might be more successful.
Abbreviations: EB, elementary body; mAb, monoclonal antibody; MOMP, major outer membrane protein; PCR, polymerase chain reaction; RB, reticulate body; TBS, Tris-buffered saline; TTBS, Tween-20-Tris-buffered saline ; VS, variable segment.
The nucleotide sequence data reported in this paper have been submitted to the EMBL, GenBank and DDBJ Nucleotide Sequence Databases and assigned the accession number M33536.
Ideally, such a vaccine should generate neutralizing mucosal antibody to the surface of the infectious EB, as well as systemic immunity, in order to prevent initial eye infection before the organisms become sequestered within host cells.
The most promising subunit vaccine candidate is the major outer membrane protein (MOMP), a porin which maintains structural rigidity of the outer envelope, regulates nutrient influx and which controls early intracellular differentiation of the chlamydiae (Bavoil et al., 1984; Hatch et al., 1984) . Immunodominant serovarand subspecies-specific epitopes on MOMP are surfaceexposed, and antibodies to them are neutralizing in uivo (Zhang et al., 1987) . By contrast, most species-and genus-specific epitopes on MOMP are inaccessible to antibody (Batteiger et al., 1986; Kuo & Chi, 1987 ; Zhang et al., 1987; Conlan et al., 1989) and thus nonneutralizing, although a surface-exposed-species-reactive MOMP epitope has been described (Collett et al., 1989) . Two B-complex-specific, surface-exposed linear epitopes (B, and B2) have been identified within variable segment 4 (VS4) of serovar B MOMP (Conlan et al., 1989) . By contrast, a C-complex-specific, surfaceexposed epitope is located within VS1 of serovar A 0001-6617 0 1991 SGM MOMP (Hayes et al., 1990) . Rabbit antisera to synthetic peptide analogues of epitopes B1, B2 and a modified analogue of the C-complex specific epitope react with the surfaces of live chlamydiae of all three trachomacausing serovars, as demonstrated by immunogold transmission electron microscopy (Conlan et al., 1989 and unpublished results) . Thus, a subunit vaccine incorporating these epitopes might protect against trachoma infection, especially if such a vaccine was engineered to elicit local, as well as systemic immunity. The necessary antigenic persistence for stimulating mucosal immunity might be achieved using a suitable live, attenuated vaccine organism.
A mouse model for chlamydial infection is available (Tuffrey et al., 1986) . When progesterone-treated C3H mice are inoculated into the uterus or ovarian bursa with a human genital tract isolate of C. trachomatis, they develop salpingitis and infertility. Since successful antigenic priming at any mucosal site, for example the gut, should protect against challenge at any other mucosal site, this model is suitable for preliminary trials of trachoma vaccine candidates.
The LamB protein of E. coli was chosen as a suitable vehicle for expression of chlamydial epitopes in the outer membrane of a live bacterial vaccine. LamB is a 47 kDa outer membrane protein which, like MOMP, is a porin and which regulates maltose transport in E. coli. The lamB gene has been cloned, placed under tac promoter control (Bouges-Bocquet et al., 1984) and engineered to create a unique BamHI site allowing insertion of foreign epitopes at amino acid position 153 of the mature LamB protein (Boulain et al., 1986) . Epitopes inserted at this site are located on a surface-exposed loop (Boulain et al., 1986; Charbit et al., 1991) . As a vaccine vector for the modified LamB protein, we chose attenuated, nonreverting aroA strains of Salmonella. These organisms colonize the mouse gut but do not multiply, protecting mice against subsequent infection with the virulent parent strains (Hoiseth & Stocker, 1981) . AroA strains have been used to elicit immune responses in mice to a variety of foreign antigens expressed both cytoplasmically (Brown et al., 1987; Poirier et al., 1988 ; Clements et al., 1986; Fairweather et al., 1990) , and at the cell surface (Charbit et al., 1987; Maskell et al., 1987; Wu et al., 1989) . This approach is potentially useful in humans since variously attenuated strains of Salmonella typhi, including aroA, are undergoing trials as live oral vaccines for use in humans (Tacket et al., 1990) .
In this study, oligonucleotides encoding two Bsubspecies epitopes of C. trachomatis were synthesized and cloned into the lamB gene. Both epitopes were incorporated into recombinant LamB proteins expressed in E. coli and S . typhimurium, and were recognized in immunoblots by polyclonal antibodies raised against synthetic peptide analogues. When administered orally to the strain of mouse used to study chlamydial salpingitis, serum IgG responses to S . typhimurium and C. trachomatis were induced but neither mucosal response nor serum IgA was detected.
Methods
Bacterial struins and vectors. Escherichiu coli JM 109 (Yanisch-Perron et ul., 1985) Epicurean competent cells were purchased from Northumbria Biologicals Limited. Salmonella typhimurium strains LB5010 (galE-, r-, m+; Bullas & Ryo, 1983) and SL3261 (aroA; Hoiseth & Stocker, 1981) and bacteriophage P22 (Schmieger, 1972) were kind gifts of Dr G. Dougan (Wellcome Research Laboratories, Beckenham, UK). The lamB vector, pAJC264 (Boulain et al., 1986) was a kind gift of Dr M. Hofnung (Institut Pasteur, Paris, France).
Enzymes. Restriction endonucleases, T4 DNA ligase and calf intestinal phosphatase were obtained from Boehringer Mannheim. T4 polynucleotide kinase was obtained from Gibco-BRL. All enzymes were used as recommended by the manufacturer.
Oligonucleotides. Complementary oligonucleotide pairs encoding epitopes B, and B2 were synthesized which utilized E. coli high expression codon preferences (Grosjean & Fiers, 1982) . The oligonucleotide pairs contained BamHI-compatible ends which recreated a BumHI site only at the 5' end of the insert when cloned into BumHI cleaved vector. Positioning of cloning sites on the oligonucleotides resulted in the addition of a proline to the N-terminus and an asparagine to the C-terminus of each epitope. Epitopes B1, B2 and the corresponding oligonucleotide sequences are shown in Fig. 1 . Oligonucleotides were synthesized using p-cyanoethyl phosphoramidite chemistry on an automated DNA synthesizer (Applied Biosystems Inc., Foster City, CA). DNA manipulations. Complementary oligonucleotide pairs were simultaneously phosphorylated with T4 polynucleotide kinase and hybridized together in 70 mM-Tris/HCl (pH 7.6), 10 m~-MgCl,, 5 mM-DTT and 500 ~M -A T P overnight at 37 "C. Oligonucleotide hybrids were ligated with BumHI-cut, dephosphorylated pAJC264 in 66 mMTris/HCl (pH 7.5),5 mM-MgCl,, 5 mM-DTT and 1 mM-ATP overnight at 4 "C. Epicurean JM109 was transformed with the recombinant plasmids according to the supplier's instructions. The constructs made are summarized in Table 1 . Recombinant plasmids were prepared by alkaline lysis (Birnboim & Doly, 1979) and purified through NACS Prepac cartridges (Gibco-BRL). S. typhimurium LB5010, a galactose epimerase mutant, was transformed with recombinant plasmids as follows: S. typhimurium LB5010, grown in LB-broth to an OD550 of 0.5, was pelleted, resuspended in 0.5 vols of 100 mM-MgCl,, incubated on ice for 20 min, pelleted again, then resuspended in one-fiftieth of the original volume of 100 rn~-CaCl,. Competent cells (200 pl) were added to 20 ng of plasmid and kept on ice for 20 min, at room temperature for 20 min, and on ice for 40 min. The cells were heat-shocked for 2 min at 42 "C, then incubated for one hour at 37 "C with 800 p1 LB-broth, and plated onto LB-agar containing 100 pg ampicillin ml-l. Overnight cultures (200 p1 samples) of recombinant S. typhimurium were incubated with dilutions of bacteriophage P22 and plated onto LB-agar containing ampicillin (100 pg ml-I). Recombinant bacteriophage P22 were harvested from plates of confluent plaques. S. typhimurium SL3261 (aroA) was transduced with recombinant 4P22 as follows: 2 0 0~1 of S. typhimurium SL3261 grown overnight in LB-broth supplemented with 1 mM-CaC12 was incubated with 1 p1 of the recombinant phage stock for one hour at 37 "C. The mixture was spread onto LB-agar containing ampicillin (75 pg ml-l) and 5 mM-EGTA. In each of the three bacterial hosts, ampicillin resistant colonies were screened by immunoblotting for expression of the required epitopes. Inserts were checked for correct frame and orientation by DNA sequencing.
Antisera. Rabbit polyclonal antisera were raised against synthetic peptide analogues of epitopes B, and B2 as previously described (Conlan et al., 1989) .
Immunoblotting. E. coli strains (400 pg protein ml-l) were disrupted by boiling for 10 rnin in 0.0625 M-Tris/HCl (pH 6-8), 2% (w/v) SDS,
bromophenol blue. Whole cell lysates were separated by SDS-PAGE on 12.5% (w/v) polyacrylamide using the Laemmli (1970) buffer system. Denatured proteins were electroblotted onto nitrocellulose (Schleicher & Schuell) at 100 mA for 90 rnin using a semi-dry blotter (Ancos, Denmark) (Khyse-Andersen, 1984). The nitrocellulose was then blocked overnight at 4 "C in Tris-buffered saline (TBS; 2.24 g Tris l-,, 26.24 g NaCl l-,, pH 7.5) containing 0.05% (v/v) Tween-20 (TTBS) and 5 % (w/v) dried skimmed milk (Marvel). Blots were incubated for 3 h at room temperature with primary antibodies diluted 1 :200 in TTBS containing 5 % (w/v) Marvel, then washed 3 x 5 rnin in TTBS. The blots were incubated for 1 h at room temperture with goat antirabbit IgG-alkaline-phosphatase conjugate (Bio-Rad) diluted 1 : 3000 in TTBS containing 5% Marvel, followed by washing for 4 x 5 rnin in TTBS, then 3 x 5 rnin in TBS. Antigen-antibody complexes were visualized using 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (Sigma) and the reactions were stopped by washing the blots in distilled water.
DNA sequencing. Cloning junctions and inserted DNA of recombinant plasmids were sequenced by the dideoxy chain termination method modified for double stranded DNA . Briefly, 3 pg of plasmid DNA was incubated for 5 min at room temperature in 0.2 MNaOH, 0.2 mM-EDTA (total volume, 20 pl). The solution was neutralized by addition of 2 p12 M-NH,-acetate (pH 4.6) and DNA was precipitated with 60 p1 100% ethanol. The DNA was pelleted, washed with 80% ethanol, repelleted, then sequenced using modified T7 polymerase (Sequenase ; Cambridge Bioscience) and [a-35S]dATP (410 Ci mmol-I; 1.5 x lo1, Bq mmol-I; Amersham). The 17mer oligonucleotides (S'AACTCTCTCTGGCAGCA and STTCGCGGTTTCGTTGGT) used to prime sequences in both directions across the inserts were based on the published sequence of the LamB gene (Clement & Hofnung, 1981) .
Separation of cytoplasmic and outer membranes of E. coli JM109 and S. typhimurium SL3261. Cytoplasmic and outer membranes of recombinant E. coli and S. typhimurium SL3261 expressing LamB containing B, + B2 were separated by the method of Osborn & Munson (1974) .
Briefly, 250 ml cultures in LB broth, induced with 0.1 mM-IPTG were pelleted, resuspended in 15 ml 0.75 M-sucrose, 10 mM-Tris-acetate pH 7.5, 100 pg lysozyme ml-l and incubated on ice for 2 min. Cells were spheroplasted by addition of 30 ml ice-cold 1.5 mM-EDTA over 10 min, then sonicated to lyse the spheroplasts. After a clearing spin, membranes were washed twice by centrifuging through 0.25 M-sucrose, 3-3 rnM-Tris/HCl and 1 mM-EDTA for 2 h at 1000oOg at 4 "C. Cytoplasmic and outer membrane fractions were separated by centrifugation at 130000g for 16 h at 4 "C through a 30-55% sucrose gradient. After centrifugation each gradient was collected in 30 fractions. Total protein content of each fraction was measured by modified Lowry assay (Ohnishi & Barr, 1978) and fractions containing protein peaks were subjected to PAGE followed by either silver staining to detect LPS (Tsai & Frasch, 1982) or immunoblotting to detect recombinant LamB.
Immunization of mice with live aroA mutants of S . typhimurium expressing B, + B2 recombinant LumB protein. Mice were immunized with a B, + B2 recombinant which possessed smooth LPS. A stock of the immunizing strain was grown in LB broth containing ampicillin (125 pg ml-l) and 0.1 mM-IPTG (16 h at 37 "C without shaking). This was harvested by centrifugation (600 g) and resuspended in PBS (Dulbecco A) containing 10% (v/v) glycerol as a cryopreservative to a total count of 2 x 10" ml-l (at 60% viability). Cells were stored frozen at -20 "C until required. A control culture of non-recombinant S. typhimurium was similarly prepared. Female C3H/He/Ola mice (Olac Ltd), 6-10 weeks old, were used in all experiments. This mouse strain was chosen because it is known to be susceptible to genital tract infections with human strains of C. trachomatis (Tuffrey et al., 1986) . On day one, 24 mice were immunized intravenously (i.v.) with 0.1 ml of the B, + B2 LamB recombinant diluted in PBS to a total count of 2 x lo6 ml-I. A further five mice received an equivalent dose of control S. typhimurium aroA. A second group of 24 mice were challenged per 0s (p.0.) with the recombinant (0.1 ml of culture at 2 x 10' ml-l total count) delivered using a gavage needle. A control group of five mice were similarly immunized with control S. typhimurium aroA. Six mice received no vaccine. All mice were housed in separate cages within the same room. At weekly intervals for six weeks, serum was obtained from mice (4 per group) which had received recombinant B, + B2 (i.v. or p.0.) by tail-vein venepuncture whilst under metafane anaesthesia. After blood samples had been taken the mice were killed by C 0 2 anoxia. The liver and spleen were removed whole from each animal aseptically into 10 ml sterile distilled water. The small intestine between the caecum and stomach was removed intact and the contents collected by washing. Sera and clarified gut washes were stored at -80 "C. Livers and spleens were homogenized for 1 rnin in a Colworth stomacher and the resulting macerates plated on LB-agar containing ampicillin for recovery of organisms. On the sixth week following immunization, all control animals were processed as above.
Determination of antibody in sera and gut-washes of immunized mice by amplijied ELISA. Antibodies to S. typhimurium aroA and C . trachomatis serovar B were detected by redox-amplified ELISA (Johannsson et al., 1985) . S. typhimurium aroA or C. trachomatis serovar B whole cells at a protein concentration of 10 pg ml-1 were coupled to microtitre PVC microtitre trays (Flow laboratories) by overnight incubation in carbonate buffer at 18 "C (1.6 g 1-l Na2C03, 2.95 g 1-l NaHCO,, 0.2 g 1-l NaN,; pH 9.6). Excess antigen was removed by washing the trays three times with 50 mM-ethanolamine/lOO mM-NaC1 (pH adjusted to 10.5 with 100 mM-citric acid). The antigen-coated, washed trays were blocked for 1 h at 37 "C with PBS (Dulbecco A) containing 5% (v/v) normal goat serum (100 p1 per well). The blocking solution was drained and test sera or gut washes added at 1 : 100 or 1 : 5 dilution respectively (50 p1 per well). The diluent was blocking solution containing 0.05% (v/v) WI detergent (Sigma). The trays were sealed and incubated for 3 h at 37 "C, then washed four times. Goat antimouse alkaline phosphatase conjugates specific for IgA or IgG (Zymed laboratories) were added at 1 :lo00 dilution (50 p1 per well) and incubation continued for 45 min. After a further six washes, NADP substrate (0.2 mM-NADP, 10 m~-MgCl,, 1 mM-ZnC12, 150 rn~-NaN, in 50 mM diethanolamine buffer, pH 9.5) was added (50 p1 per well). This solution was filtered through a 0.22 pm filter immediately before use. Incubation continued for 40 rnin at 18 "C. 
288S A E T I F D V T T L N P T I A G A G D V K T S A E G Q L G317

I I I I I I I I I I I (P) S A E T I F D V T T L (D)
epitope B,
I I I I I I I I I I I (P) L N P T I A G A G D V (D)
epitope B, (6) Epitope B, :
' G A T CCG T C T GCT GAA ACC ATC T T C GAC G T T ACC ACC CTC 3 '
GC AGA CGA C T T TGG TAG AAG CTG CAA TGG TGG GAG CTA G Epitope B2: 
' G A T CCG CTG AAC CCG ACC ATC GCT GGT GCT GGT GAC G T T 3 ' GC GAC T T G GGC TGG TAG
Results and Discussion
Expression of epitopes in E. coli C. trachomatis epitopes B1 and B2 are shown in Fig. 1 ; they are identical to the sequences occurring in C. trachomatis serovar B/Jali-20/0T VS4 (Hayes et al., 1990) . Sequence B contains the known B-complexspecific, surface-exposed epitope IFDV (Conlan et al., 1988) . Sequence B2 contains a species-specific epitope, LNPTIA, which is not surface-exposed (Stephens et al., 1988; Conlan et al., 1988; Baehr et al., 1988) as well as an additional surface exposed, B-complex specific region AGDV (Conlan et al., 1989) . Epitopes B1 and B2 were expressed as fusions with LamB both individually and in tandem, as shown in Table 1 . An additional sequence from VS1 of serovar A, containing serovar A-and Csubspecies-specific epitopes (Hayes et al., 1990) was expressed in S. typhimurium aroA but was not used for animal inoculations since it was poorly detected in Western blots and the recombinant salmonellae expressing this epitope consistently possessed rough LPS.
Immunoblots of E. coli strains expressing epitopes B1 and B2 as recombinant LamB proteins are shown in Fig.  2 (a and b) . In VS4 of serovar-B MOMP, the sequence 2*8SAETIFDVTTLNPTIAGAGDV308 contains epitopes B1 (residues 288-298) and B2 (residues 298-308) which overlap each other by one amino acid. Interest- peared to express both epitopes, since a non-truncated recombinant protein was obtained. However, only the proximal B2 was detected by immunoblotting (data not shown). DNA sequencing confirmed the correct orientation of both epitopes in the double recombinant. Presumably the lack of reactivity of B1 in this construct reflects stoichiometric constraints on the ordering of epitopes within the LamB vector.
Expression of epitopes in S. typhimurium SL3261
S. typhimurium SL3261 (aroA) was transduced with 4P22 carrying recombinant plasmids, since direct transformation of smooth Salmonella strains is very inefficient (MacLachlan & Sanderson, 1985) and selects for rough mutants (Brown et al., 1987) . The receptor for 4P22 is not present on rough salmonellae, ensuring that transductants are smooth. Only smooth salmonellae will colonize mice. Fig. 2c shows immunoblots of S. typhimurium SL326 1 expressing recombinant LamB fused with epitopes B1 + BZ. These epitopes were expressed in S. typhimurium SL3261 at equivalent levels to those observed in E. coli JM109.
Location of recombinant LamB proteins within the bacterial outer membrane
To verify the location of the expressed proteins, cytoplasmic and outer membrane fractions of recombinant E. coli and S. typhimurium were separated by sucrose density gradient centrifugation, then subjected to PAGE followed by silver staining (Fig. 3a and b) . The outer membrane component LPS was located in fractions towards the bottom of the gradient. In identical gels immunoblotted and probed with anti-B, (Fig. 3c and d) , the recombinant LamB protein was located exclusively in those fractions which contained LPS, indicating that it is present in the outer membrane in both E. coli and S. typhimurium. From the proposed model of LamB folding (Boulain et al., 1986; Charbit et al., 1991) it would be expected that the inserted C. trachomatis epitopes should reside within a surface-exposed loop. However, attempts to label these epitopes at the surfaces of recombinant E. coli and S . typhimurium with immunogold were unsuccessful. The long side chain of smooth LPS may prevent antibody binding to the surface-exposed LamB, blocking surface labelling of the recombinant bacteria with immunogold. However, Brown et al. (1987) demonstrated that expression at the surface of salmonellae is not necessary to provoke B-and T-cell responses to cloned proteins. These were the first experiments to use recombinant chlamydial antigens expressed in salmonellae to elicit immune responses in the mouse model of chlamydia1 infection. Ampicillin-resistant bacteria were recovered from the livers of mice immunized i.v. for up to two weeks post-challenge and from the spleens of these animals for up to four weeks (Table 2) . Bacteria were also recovered from the livers of p.0. immunized mice for up to two weeks. However, no bacteria were isolated from the spleens of p.0. immunized animals after the first week. In all cases the numbers of bacteria recovered were low (10-30 organisms per organ) and they were confirmed to be carrying the recombinant lamB plasmid by PCR, using as primers the lamB-specific oligonucleotides described above (data not shown).
Detection of antibodies in immunized mice to S . typhimurium and C. trachomatis
A live attenuated S . typhimurium aroA mutant containing recombinant LamB protein incorporating C. trachomatis epitopes B, + B2 was assessed for its ability to generate anti-chlamydia1 antibodies when inoculated into mice. Two routes of administration were tried; i.v. immunization with S . typhimurium aroA expressing LamB (B, + B2), which produced circulating IgG antibody to S . typhimurium and to C. trachomatis in only 5/24 and 3/24 animals respectively (Fig. 4a) , and oral immunization, which produced circulating IgG to S . typhimurium in 15/19 animals although only 5/19 had circulating IgG to C. trachomatis (Fig. 4b) . Antibody titres to C. trachomatis were generally much lower than for S . typhimurium, as would be expected given the much lower mass of chlamydial epitopes. There was little correlation between the levels of antibody to S . typhimurium and C. trachomatis in the p.0. immunized animals. Neither IgA nor IgG antibodies to either S. typhimurium or C. trachomatis were detected in the gut washes, nor was IgA antibody to either antigen detected in the sera.
Brown et al. (1987) elicited high-titre antibodies to pgalactosidase expressed as cytoplasmic inclusions in S . typhimurium aroA when intravenously administered. However, this group used a different strain of mouse (BIOXA/J) to that used in the present study. Moreover, the P-galactosidase in their immunogen represented up to 2% of the total protein whereas the C. trachomatisspecific epitope present in our vaccine strain was much less than this as judged subjectively by the quantity of LamB present on SDS-PAGE profiles. By contrast to i.v. immunization, p.0. administration of the recombinant LamB aroA strain resulted in seroconversion of IgG antibody to S . typhimurium in the majority of mice. This may simply be a reflection of the larger dose of bacteria given p.0. compared to i.v.; however, it was not accompanied by increased colonization of the liver or spleen. Oral immunization produced an antibody response to C . trachomatis in significantly more animals than did i.v. immunization. However, the total number of mice responding and the antibody titres remained low. Charbit et al. (1987) also found only low levels of antibody to a hepatitis B virus epitope inserted into the LamB protein, although this group used E. coli rather than S. typhimurium as the bacterial host. Leclerc et al. (1989) found the route of inoculation to be important; i.v. and i.p. administration of live recombinant E. coli being more effective than subcutaneous administration, however, mucosal immunity was not sought by those authors. Surprisingly, no IgA antibody to C. trachomatis or to S. typhimurium was found in any of the test samples, including the sera. Maskell et al. (1987) using S. typhimurium aroA mutants expressing the B subunit of E. coli heat labile toxin, demonstrated a consistent IgA response in both the sera and gut washes of recipient Balb/C mice. In that study, the livers and spleens of orally-immunized mice were colonized by bacteria for up to 5 weeks, longer than in the present study, which might partly explain the differences in IgA production. Sigwart et al. (1989) also demonstrated IgA antibodies to S. dublin aroA in orally immunized Balb/C mice. In their study, colonization of the liver and spleen was similar to the results reported here, but S. dublin was recovered from the small intestine for up to 3 weeks following oral administration. In our study, the recombinant S. typhimurium was cleared rapidly (8 d) from the small intestine of C3H/He/Ola mice. Long-term colonization of the small intestine and particularly the gut-associated lymphoid tissue (GALT) should favour a local IgA response, thus the transient passage of S. typhimurium through the gut observed here is probably an insufficient stimulus to elicit secretory IgA. This may reflect the mouse strain we used; C3H/He/Ola mice are susceptible to chlamydial salpingitis (Tuffrey et al., 1986) but are less susceptible to natural S. typhimurium infections than Balb/C mice (Hormaeche, 1979) . Moreover, surface expression of the recombinant LamB protein might also alter the colonization properties of S. typhimurium. Thus the mouse and Salmonella strain, the carrier protein and the properties of the inserted epitopes are all likely to influence the immunogenicity of attenuated Salmonella constructs in mice.
At least one attenuated Salmonella, S. typhi Ty21 a, has already proved acceptable for use in man. In some systems Salmonella vectors have achieved adequate mucosal immunity. Our results suggest this may not be true of all systems, indicating a need to modify our vaccination strategy if effective mucosal immunization is to be achieved. The choice of mouse strain is limited by murine genotypic factors affecting the establishment of colonization and chlamydial salpingitis. We believe that the strategy should be to identify a stable Salmonella host capable of colonizing the mouse intestine for 3-4 weeks following oral administration. There is a considerable range of S. typhimurium and S. enteritidis strains to choose from (reviewed by Curtiss et al., 1989) . Secondly, the ability of the chlamydial-Salmonella recombinant to colonize the mouse gut should be determined prior to immunization and challenge studies. Finally, incorporation of T-cell epitopes of MOMP (Allen et al., 1990; Holland et al., 1990) as well as important neutralizing epitopes from other chlamydial surface antigens may enhance the immunogenicity of the constructs. Brown et al. (1987) have demonstrated that cloned antigens expressed in aroA mutants of S. typhimurium can induce cellular as well as humoral immune responses. Each model system of human infection may pose its own problems. We believe such studies to be of fundamental importance, given the present inability to control a large number of diseases affecting respiratory, mucosal and ocular surfaces by immunization.
